Fig. 1From: Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-seriesTherapy timelines for patients in relation to rash onset showing sequencing of ICB and TTBack to article page